Oxymorphone controlled release formulations
DC CAFCFirst Claim
Patent Images
1. An oral controlled release oxymorphone formulation, comprising:
- a. about 5 mg to about 80 mg of oxymorphone or a pharmaceutically acceptable salt of oxymorphone; and
b. a hydrophilic material,wherein upon oral administration of the formulation to a subject in need of an analgesic effect;
(i) the formulation provides detectable blood plasma levels of 6-OH oxymorphone and oxymorphone;
(ii) the blood plasma levels of 6-OH oxymorphone and oxymorphone peak within about 1 hour to about 8 hours after administration;
(iii) the blood plasma levels of 6-OH oxymorphone and oxymorphone exhibit a ratio of area under the curve (AUC(0 to inf)) of blood plasma level versus time for 6-OH oxymorphone compared to oxymorphone in a range of about 0.5 to about 1.5;
(iv) the duration of the analgesic effect is through at least about 12 hours after administration; and
(v) the blood plasma levels of oxymorphone exhibit two or three peaks within about 12 hours after administration.
10 Assignments
Litigations
2 Petitions
Accused Products
Abstract
The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.
203 Citations
82 Claims
-
1. An oral controlled release oxymorphone formulation, comprising:
-
a. about 5 mg to about 80 mg of oxymorphone or a pharmaceutically acceptable salt of oxymorphone; and b. a hydrophilic material, wherein upon oral administration of the formulation to a subject in need of an analgesic effect; (i) the formulation provides detectable blood plasma levels of 6-OH oxymorphone and oxymorphone; (ii) the blood plasma levels of 6-OH oxymorphone and oxymorphone peak within about 1 hour to about 8 hours after administration; (iii) the blood plasma levels of 6-OH oxymorphone and oxymorphone exhibit a ratio of area under the curve (AUC(0 to inf)) of blood plasma level versus time for 6-OH oxymorphone compared to oxymorphone in a range of about 0.5 to about 1.5; (iv) the duration of the analgesic effect is through at least about 12 hours after administration; and (v) the blood plasma levels of oxymorphone exhibit two or three peaks within about 12 hours after administration. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
-
-
13. A pharmaceutical tablet prepared by:
-
a. mixing oxymorphone or a pharmaceutically acceptable salt of oxymorphone and controlled release granules comprising a hydrophilic material and one or more optional excipients; and b. directly compressing the mixture of (a) to form the tablet, wherein upon placement of the tablet in an in vitro dissolution test comprising USP Paddle Method at 50 rpm in 500 ml media having a pH of 1.2 to 6.8 at 37°
C., about 15% to about 50%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 1 hour in the test. - View Dependent Claims (14, 15, 16, 17, 18, 19, 20)
-
-
21. A pharmaceutical tablet prepared by:
-
a. mixing oxymorphone or a pharmaceutically acceptable salt of oxymorphone and one or more controlled release excipients; and b. forming the tablet, wherein upon placement of the tablet in an in vitro dissolution test comprising USP Paddle Method at 50 rpm in 500 ml media having a pH of 1.2 to 6.8 at 37°
C., about 15% to about 50%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 1 hour in the test; and
wherein upon oral administration to a human subject the tablet alleviates pain for 12 to 24 hours. - View Dependent Claims (22, 23, 24, 25, 26, 27, 28, 29, 30)
-
-
31. A method for treating pain in a human subject in need of acute or chronic pain relief, comprising the steps of:
-
(a) Providing a solid oral dosage form of a controlled release oxymorphone formulation with a release rate profile designed to provide adequate blood plasma levels over at least 12 hours to provide sustained pain relief over this same period comprising about 5 mg to about 80 mg oxymorphone or a pharmaceutically acceptable salt thereof wherein oxymorphone is the sole active ingredient, and wherein upon placement of the composition in an in vitro dissolution test comprising USP Paddle Method at 50 rpm in 500 ml media having a pH of 1.2 to 6.8 at 37°
C., about 15% to about 50%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 1 hour in the test; and(b) administering a single dose of the dosage form to the subject, wherein the oxymorphone Cmax is at least 50% higher when the dosage form is administered to the subject under fed as compared to fasted conditions. - View Dependent Claims (32, 33, 34, 35, 36, 37)
-
-
38. A method for treating pain in a human subject in need of acute or chronic pain relief, comprising the steps of:
-
(a) Providing a solid oral dosage form comprising about 5 mg to about 80 mg oxymorphone or a pharmaceutically acceptable salt thereof in a controlled release delivery system with a release rate profile designed to provide adequate blood plasma levels over at least 12 hours to provide sustained pain relief over this same period, wherein oxymorphone is the sole active ingredient, and wherein upon placement of the composition in an in vitro dissolution test comprising USP Paddle Method at 50 rpm in 500 ml media having a pH of 1.2 to 6.8 at 37°
C., about 15% to about 50%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 1 hour in the test, about 45% to about 80%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 4 hours in the test, and at least about 80%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 10 hours in the test; and(b) administering a single dose of the dosage form to the subject, wherein the oxymorphone Cmax is at least 50% higher when the dosage form is administered to the subject under fed versus fasted conditions. - View Dependent Claims (39, 40, 41, 42, 43, 44, 45, 46, 47, 48)
-
-
49. An analgesically effective controlled release pharmaceutical composition for oral delivery, comprising:
-
a. a controlled release delivery system with a release rate profile designed to provide adequate blood plasma levels over at least 12 hours to provide sustained pain relief over this same period; and b. about 5 mg to about 80 mg of oxymorphone or a pharmaceutically acceptable salt of oxymorphone, wherein oxymorphone is the sole active ingredient, wherein upon oral administration of a single dose of the composition to a human subject, the oxymorphone Cmax is at least 50% higher when the dose is administered to the subject under fed as compared to fasted conditions, and wherein upon placement of the composition in an in vitro dissolution test comprising USP Paddle Method at 50 rpm in 500 ml media having a pH of 1.2 to 6.8 at 37°
C., about 15% to about 50%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 1 hour in the test. - View Dependent Claims (50, 51, 52, 53, 54)
-
-
55. An analgesically effective controlled release pharmaceutical composition for oral delivery, comprising:
-
a. a controlled release delivery system with a release rate profile designed to provide adequate blood plasma levels of oxymorphone and 6-hydroxy-oxymorphone over at least 12 hours to provide sustained pain relief over this same period; and b. about 5 mg to about 80 mg of oxymorphone or a pharmaceutically acceptable salt of oxymorphone, wherein oxymorphone is the sole active ingredient, wherein upon placement of the composition in an in vitro dissolution test comprising USP Paddle Method at 50 rpm in 500 ml media having a pH of 1.2 to 6.8 at 37°
C., about 15% to about 50%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 1 hour in the test. - View Dependent Claims (56, 57, 58, 59, 60, 61, 62, 63, 64, 65)
-
-
66. An analgesically effective controlled release pharmaceutical composition for oral delivery, comprising:
-
a. a controlled release delivery system with a release rate profile designed to provide adequate blood plasma levels over at least 12 hours to provide sustained pain relief over this same period; and b. about 5 mg to about 80 mg of oxymorphone or a pharmaceutically acceptable salt of oxymorphone, wherein oxymorphone is the sole active ingredient, wherein upon placement of the composition in an in vitro dissolution test comprising USP Paddle Method at 50 rpm in 500 ml media having a pH of 1.2 to 6.8 at 37°
C., about 15% to about 50%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 1 hour in the test, and wherein upon oral administration of the composition to a human subject, the blood plasma levels of oxymorphone comprise one or more peaks. - View Dependent Claims (67, 68, 69, 70, 71)
-
-
72. A controlled release pharmaceutical composition comprising oxymorphone or a pharmaceutically acceptable salt thereof as the sole active ingredient and a controlled release matrix, comprising about 10% to about 75% (by total weight of the controlled release matrix) of a gelling agent which forms a gel upon exposure to gastrointestinal fluid;
wherein upon placement of the composition in an in vitro dissolution test comprising USP paddle method at 50 rpm in 500 ml media having a pH of 1.2 to 6.8 at 37°
C., about 15% to about 50%, by weight, of the oxymorphone or salt thereof is released from the composition after about 1 hour in the test.- View Dependent Claims (73, 74, 75, 76, 81)
-
77. A controlled release pharmaceutical composition comprising oxymorphone or pharmaceutically acceptable salt thereof as the sole active ingredient, and a controlled release matrix comprising about 10% to about 75% (by total weight of the controlled release matrix) of a gelling agent which forms a gel upon exposure to gastrointestinal fluid;
-
wherein upon placement of the composition in an in vitro dissolution test comprising USP paddle method at 50 rpm in 500 ml media having a pH of 1.2 to 6.8 at 37°
C., about 15% to about 50%, by weight, of the oxymorphone or salt thereof is released from the composition after about 1 hour in the test, about 45% to about 80%, by weight, of the oxymorphone or salt thereof is released from the composition after about 4 hours in the test, and at least 80%, by weight, of the oxymorphone or salt thereof is released from the composition after about 10 hours in the test,wherein upon oral administration of a single dose of the composition to a human subject, the composition provides an oxymorphone Cmax of at least 50% higher when the dose is administered to the subject under fed as compared to fasted conditions and provides a difference in oxymorphone AUC(0-inf) of less than 20% higher when the dose is administered to the subject under fed as compared to fasted conditions. - View Dependent Claims (78, 79, 80, 82)
-
Specification